Ebola: Symptoms, treatment, and causes
Resolution Of Pansclerotic Morphea After Treatment With Antithymocyte Globulin
Diaz-Perez, J. L., Connolly, S. M. & Winkelmann, R. K. Disabling pansclerotic morphea of children. Arch. Dermatol. 116, 169–173 (1980).
Maragh, S. H., Davis, M. D., Bruce, A. J. & Nelson, A. M. Disabling pansclerotic morphea: clinical presentation in two adults. J. Am. Acad. Dermatol. 53 (2 Suppl. 1), S115–S119 (2005).
Herzinger, T., Prinz, J. C. & Röcken, M. Pansclerotic morphea of the head. Arch. Dermatol. 144, 125–126 (2008).
Haustein, U. F. Scleroderma and pseudo-scleroderma: uncommon presentations. Clin. Dermatol. 23, 480–490 (2005).
Boin, F. & Hummers, L. K. Scleroderma-like fibrosing disorders. Rheum. Dis. Clin. North Am. 34, 199–220 (2008).
Westerman, M. P., Martinez, R. C., Medsger, T. A. Jr, Totten, R. S. & Rodnan, G. P. Anemia and scleroderma: frequency, causes, and marrow findings. Arch. Intern. Med. 122, 39–42 (1968).
Doyle, J. A., Connolly, S. M. & Winkelmann, R. K. Cutaneous and subcutaneous inflammatory sclerosis syndromes. Arch. Dermatol. 118, 886–890 (1982).
Kamada, K. Et al. Scleroderma associated with anemia and thrombocytopenia that responded well to cyclosporin. Acta Haematol. 104, 106–109 (2000).
Tooze, J. A. Et al. Response of aplastic anaemia and scleroderma to cyclosporin. Br. J. Haematol. 85, 829–831 (1993).
Ivey, K. J., Hwang, Y. F. & Sheets, R. F. Scleroderma associated with thrombocytopenia and Coombs-positive hemolytic anemia. Am. J. Med. 51, 815–817 (1971).
Peterson, L. S., Nelson, A. M. & Su, W. P. Classification of morphea (localized scleroderma). Mayo Clin. Proc. 70, 1068–1076 (1995).
Bielsa, I. & Ariza, A. Deep morphea. Semin. Cutan. Med. Surg. 26, 90–95 (2007).
Rosenfeld, S., Follmann, D., Nunez, O. & Young, N. S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289, 1130–1135 (2003).
Xie, Y. Et al. Immunohistochemical characterization of the cellular infiltrate in localized scleroderma. Int. J. Dermatol. 47, 438–442 (2008).
Denton, C. P., Korn, J. H., Black, C. M. & de Crombrugghe, B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 347, 1453–1458 (1996).
Stratton, R. J., Wilson, H. & Black, C. M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40, 84–88 (2001).
Suematsu, E., Miyamura, T., Idutsu, K., Minami, R. & Yamamoto, M. Efficacy of anti-thymocyte globulin and cyclosporin A combined therapy in aplastic anemia complicated with limited cutaneous systemic sclerosis [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 28, 99–103 (2005).
Mothy, M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21, 1387–1394 (2007).
Graham, Lauren, M.D., Ph.D.
Associate ProfessorVice Chair, Clinical Affairs; Ambulatory Medical and Quality Officer
Areas of Interest- Fibrotic skin diseases (morphea, scleroderma),- Dermatology/Rheumatology
BiographyDr. Graham is interested in Medical Dermatology. She has a specific interest in autoimmune blistering diseases and rheumatological skin diseases like cutaneous lupus, morphea, psoriasis, and dermatomyositis.
Certifications Education & TrainingMedical SchoolUniversity of Alabama at Birmingham
Graduate SchoolUniversity of Alabama at Birmingham
InternshipBaptist Health System
Dermatology ResidencyNorthwestern University
Contact InformationLatrice UnderwoodProgram Coordinator IIPhone: (205) 996-1008Email: latriceunderwood@uabmc.Edu
Comments
Post a Comment